Summary of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings on May 17, 2018

May 17, 2018 - By Linda Ocallaghan

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Corporate Logo
Big Money Sentiment increased to 1.66 in Q4 2017. It has change of 0.40, from 2017Q3’s 1.26. The ratio improved due to Halozyme Therapeutics, Inc. positioning: 13 sold and 45 reduced. 39 funds bought positions and 57 increased positions. Investors holded 118.53 million in 2017Q3 but now own 118.31 million shares or 0.18% less.
Atlantic Trust Grp Ltd Liability holds 22,801 shs or 0% of its capital. California State Teachers Retirement Systems has invested 0.01% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO). National Bank & Trust Of Montreal Can stated it has 2,550 shs or 0% of all its holdings. Prudential accumulated 909,286 shs. Ubs Asset Mngmt Americas holds 84,321 shs or 0% of its capital. Cubist Systematic Strategies Lc holds 26,290 shs. Employees Retirement Association Of Colorado owns 27,999 shs for 0% of their capital. 32,800 are held by Sector Pension Inv Board. 12,200 were reported by Numeric Investors Limited Liability Company. Citigroup Inc stated it has 182,985 shs or 0% of all its holdings. Deutsche Fincl Bank Ag owns 763,136 shs for 0.01% of their capital. Credit Suisse Ag reported 123,772 shs. Millennium Management Ltd Liability Corporation stated it has 1.48 million shs or 0.04% of all its holdings. Artal Grp Inc reported 0.05% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Amalgamated Bankshares invested in 0.01% or 16,247 shs.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

In total 6 analysts cover Halozyme (NASDAQ:HALO). “Buy” rating has 3, “Sell” are 1, while 2 are “Hold”. (NASDAQ:HALO) has 50% bullish analysts. 9 are the (NASDAQ:HALO)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Thursday, February 22 the stock has “Market Perform” rating by BMO Capital Markets. On Wednesday, February 21 the rating was maintained by JP Morgan with “Overweight”. On Wednesday, November 22 the stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) earned “Hold” rating by Barclays Capital. On Friday, May 11 the stock has “Underweight” rating by Barclays Capital. On Wednesday, January 24 Deutsche Bank maintained the shares of HALO in report with “Buy” rating. The stock rating was maintained by Canaccord Genuity with “Buy” on Wednesday, February 21. In Monday, May 14 report Canaccord Genuity maintained the stock with “Buy” rating. Listed here are Halozyme Therapeutics, Inc. (NASDAQ:HALO) PTs and latest ratings.

14/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0000 Maintain
11/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Old Target: $19 Downgrade
22/02/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $18 New Target: $19 Maintain
21/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0 Maintain
21/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $19 New Target: $22 Maintain
24/01/2018 Broker: Deutsche Bank Rating: Buy New Target: $21.0 Maintain
24/01/2018 Broker: Goldman Sachs Rating: Neutral New Target: $20 Initiates Coverage On
17/01/2018 Broker: BMO Capital Markets Rating: Hold New Target: $18.0
22/11/2017 Broker: Barclays Capital Rating: Hold New Target: $19.0 Downgrade

The stock decreased 2.47% or $0.46 during the last trading session, hitting $18.16.Currently Halozyme Therapeutics, Inc. is uptrending after 32.10% change in last May 17, 2017. HALO has also 644,666 shares volume. The stock outperformed the S&P500 by 20.55%.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally.The company has $2.60 billion market cap. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.40.36 is the P/E ratio. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

More recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were brought out by Benzinga.com, Benzinga.com and Seekingalpha.com. The first one has “22 Stocks Moving In Friday’s Pre-Market Session” as a title and was brought out on May 11, 2018. The next is “38 Stocks Moving In Friday’s Mid-Day Session” on May 11, 2018. And last was brought out on May 11, 2018, called “Premarket analyst action – healthcare”.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.